Literature DB >> 24375195

Clinical significance and biological roles of CRKL in human bladder carcinoma.

Bin Han1, Lan Luan, Zhenqun Xu, Bin Wu.   

Abstract

CRKL encodes an adaptor protein that has been recently reported to be overexpressed in various cancers and associate with the malignant behavior of cancer cells. However, the expression pattern of CRKL protein and its clinical significance in human bladder cancer have not been well characterized to date. In the present study, CRKL expression was analyzed in 82 archived bladder cancer specimens using immunohistochemistry, and the correlations between CRKL expression and clinicopathological parameters were evaluated. We found that CRKL was overexpressed in 31 of 82 (37.8%) bladder cancer specimens. A significant association was observed between CRKL overexpression and tumor status (p = 0.019). To further explore the biological functions of CRKL in bladder cancer, we overexpressed CRKL in BIU-87 and 5637 cell lines. Using CCK8 assay and colony formation assay, we showed that CRKL upregulation increased cell proliferation. In addition, transwell assay showed that CRKL could also facilitate invasion. Further study demonstrated that CRKL upregulation increased cyclin D1 expression and ERK phosphorylation. In conclusion, CRKL is overexpressed in bladder cancer and regulates malignant cell growth and invasion, which makes CRKL a candidate therapeutic target for bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24375195     DOI: 10.1007/s13277-013-1536-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  26 in total

1.  Hypermethylation in bladder cancer: biological pathways and translational applications.

Authors:  Marta Sánchez-Carbayo
Journal:  Tumour Biol       Date:  2012-01-25

2.  Active (p)CrkL is overexpressed in human malignancies: potential role as a surrogate parameter for therapeutic tyrosine kinase inhibition.

Authors:  Christian F Singer; Gernot Hudelist; Wolfgang Lamm; Ruth Mueller; Claudia Handl; Ernst Kubista; Klaus Czerwenka
Journal:  Oncol Rep       Date:  2006-02       Impact factor: 3.906

3.  CrkL plays a role in SDF-1-induced activation of the Raf-1/MEK/Erk pathway through Ras and Rac to mediate chemotactic signaling in hematopoietic cells.

Authors:  Ayako Arai; Mae Aoki; Yan Weihua; Aishun Jin; Osamu Miura
Journal:  Cell Signal       Date:  2006-05-16       Impact factor: 4.315

Review 4.  Gene-based urinary biomarkers for bladder cancer: an unfulfilled promise?

Authors:  Nikhil Sapre; Paul D Anderson; Anthony J Costello; Christopher M Hovens; Niall M Corcoran
Journal:  Urol Oncol       Date:  2013-10-17       Impact factor: 3.498

5.  Radiotherapy plus chemotherapy in muscle-invasive bladder cancer.

Authors:  Carl D Atkins; Stephen H Wrzesinski
Journal:  N Engl J Med       Date:  2012-07-26       Impact factor: 91.245

6.  Overexpression of CRKL correlates with poor prognosis and cell proliferation in non-small cell lung cancer.

Authors:  Yan Wang; Qian-ze Dong; Ling Fu; Maggie Stoecker; Endi Wang; En-Hua Wang
Journal:  Mol Carcinog       Date:  2012-06-29       Impact factor: 4.784

Review 7.  Regulation of cyclin D1 gene expression.

Authors:  Ini-Isabée Witzel; Li Fang Koh; Neil D Perkins
Journal:  Biochem Soc Trans       Date:  2010-02       Impact factor: 5.407

8.  Interleukin-5 enhances the migration and invasion of bladder cancer cells via ERK1/2-mediated MMP-9/NF-κB/AP-1 pathway: involvement of the p21WAF1 expression.

Authors:  Eo-Jin Lee; Se-Jung Lee; Sangtae Kim; Seok-Cheol Cho; Yung Hyun Choi; Wun-Jae Kim; Sung-Kwon Moon
Journal:  Cell Signal       Date:  2013-06-11       Impact factor: 4.315

9.  Heregulin beta1 promotes breast cancer cell proliferation through Rac/ERK-dependent induction of cyclin D1 and p21Cip1.

Authors:  Chengfeng Yang; Eric A Klein; Richard K Assoian; Marcelo G Kazanietz
Journal:  Biochem J       Date:  2008-02-15       Impact factor: 3.857

10.  Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer.

Authors:  Y H Kim; K A Kwei; L Girard; K Salari; J Kao; M Pacyna-Gengelbach; P Wang; T Hernandez-Boussard; A F Gazdar; I Petersen; J D Minna; J R Pollack
Journal:  Oncogene       Date:  2009-12-07       Impact factor: 9.867

View more
  5 in total

1.  Crk-like adapter protein regulates CCL19/CCR7-mediated epithelial-to-mesenchymal transition via ERK signaling pathway in epithelial ovarian carcinomas.

Authors:  Shaomei Cheng; Jingyan Guo; Qing Yang; Xiangshan Yang
Journal:  Med Oncol       Date:  2015-01-31       Impact factor: 3.064

2.  SOX10 is over-expressed in bladder cancer and contributes to the malignant bladder cancer cell behaviors.

Authors:  H Yin; C Qin; Y Zhao; Y Du; Z Sheng; Q Wang; Q Song; L Chen; C Liu; T Xu
Journal:  Clin Transl Oncol       Date:  2017-03-03       Impact factor: 3.405

3.  The Immunohistochemical Expression of SOX-10 in Urothelial Carcinoma and the Non Neoplastic Urothelium; and a Correlation with the Tumor Features.

Authors:  Samar Amer; Heba Ibrahim; Miran Elkordy
Journal:  Asian Pac J Cancer Prev       Date:  2022-04-01

4.  CRKL oncogene is downregulated by p53 through miR-200s.

Authors:  Miyuki Tamura; Yasushi Sasaki; Kenta Kobashi; Kousuke Takeda; Takafumi Nakagaki; Masashi Idogawa; Takashi Tokino
Journal:  Cancer Sci       Date:  2015-07-14       Impact factor: 6.716

5.  Lidocaine enhances the effects of chemotherapeutic drugs against bladder cancer.

Authors:  Xihua Yang; Lili Zhao; Meiping Li; Lei Yan; Shengwan Zhang; Zhenguo Mi; Liansheng Ren; Jun Xu
Journal:  Sci Rep       Date:  2018-01-12       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.